Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

Published:2019-07-22 Issue:13 Volume:134 Page:1024-1036
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Goy Andre¹,Ramchandren Radhakrishnan²,Ghosh Nilanjan³,Munoz Javier⁴,Morgan David S.⁵,Dang Nam H.⁶,Knapp Mark⁷,Delioukina Maria⁸,Kingsley Edwin⁹,Ping Jerry¹⁰,Beaupre Darrin M.¹⁰,Neuenburg Jutta K.¹⁰,Ruan Jia¹¹

Affiliation:

1. John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ;

2. Karmanos Cancer Institute, Wayne State University, Detroit, MI;

3. Levine Cancer Institute, Charlotte, NC;

4. Banner MD Anderson Cancer Center, Gilbert, AZ;

5. Vanderbilt-Ingram Cancer Center, Nashville, TN;

6. Division of Hematology/Oncology, University of Florida, Gainesville, FL;

7. Mid Ohio Oncology/Hematology, Inc, Columbus, OH;

8. Johnson & Johnson, Horsham, PA;

9. Comprehensive Cancer Centers of Nevada, Las Vegas, NV;

10. Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA; and

11. Division of Hematology & Medical Oncology, Weill Cornell Medical College, New York, NY

Abstract

AbstractThe investigators report on the promising activity of a phase 1b trial of the targeted therapy triplet rituximab, ibrutinib, and lenalidomide in patients with relapsed non–germinal center diffuse large B-cell lymphoma (DLBCL).

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/134/13/1024/1222966/blood891598.pdf

Reference29 articles.

1. Relapsed/refractory diffuse large B-cell lymphoma;Friedberg;Hematology Am Soc Hematol Educ Program,2011

2. Guidelines for the management of diffuse large B-cell lymphoma;Chaganti;Br J Haematol,2016

3. Incidence and survival of hematological cancers among adults ages ≥75 years;Krok-Schoen;Cancer Med,2018

4. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study;Crump;Blood,2017

5. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol,2010

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127;Science;2024-02-02

2. Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies;Journal of Medicinal Chemistry;2024-02-01

3. The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantation;Oncohematology;2024-01-25

4. Second Line Treatment of DLBCL: Evolution of Options;Seminars in Hematology;2023-12

5. Zanubrutinib-lenalidomide-rituximab (ZR2) in unfit diffuse large B-cell lymphoma: efficient and tolerant;Annals of Hematology;2023-11-14